Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 9, Issue 9, Pages 510-519Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2012.111
Keywords
-
Categories
Funding
- NIH [P01CA094237, P50CA126752, U54HL08100]
- SCOR award from the Leukemia and Lymphoma Society
Ask authors/readers for more resources
Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available